Program
QL2108
A development code. Also written as “QL2108 injection”.
Its studies are mostly in Dermatitis, Atopic, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 21 open or running | phase 3since Mar 13, 2025 | Sep 24, 2024 | May 2027phase 3 · NCT06884891 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06614907 · 198 enrolled · China
- Mar 13, 2025Phase 3 study in Dermatitis, AtopicNCT06884891 · 520 planned
Ahead
- May 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06884891
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06884891Dermatitis, Atopic | 3 | Not yet recruiting | May 2027 | 520 |
| NCT06614907Dermatitis, Atopic · China | 1 | Completed | Nov 15, 2024 | 198 |
How it is read
Names in the registry
- “QL2108 injection”, 2 entries
Codes read as this program: QL2108.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.